Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627935 | 0.91 | ROCK2 (0.52) | ROCK2ROCK1ACACB | |
| SCHEMBL29627955 | 0.88 | ROCK2 (0.42) | ROCK2ROCK1KDM4EACACB | |
| SCHEMBL29627925 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1ACACB | |
| SCHEMBL29640795 | 0.87 | ROCK2 (0.42) | ROCK2ROCK1KDM4EKMT2AHPGD | |
| SCHEMBL29627983 | 0.86 | SCN9A (0.45) | ROCK2ROCK1ACACBHPGDS | |
| SCHEMBL29627937 | 0.85 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL29627697 | 0.84 | ROCK2 (0.40) | ROCK2ROCK1 | |
| SCHEMBL29627828 | 0.84 | ROCK2 (0.58) | ROCK2ROCK1 | |
| SCHEMBL29640972 | 0.83 | ROCK2 (0.51) | ROCK2ROCK1 | |
| SCHEMBL20769697 | 0.81 | ROCK2 (0.55) | ROCK2ROCK1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885KDM4E 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.